Until now, targeted therapy against a KRAS-mutation at p.12GC with sotarasib has only been approved for lung and colorectal cancer by the Federal Drug Administration (FDA) and European Medical Association (EMA) (Skoulidis et al. 2021; Fakih et al. 2022; de Langen et al. 2023). Here, KRAS is linked to colorectal cancer.